Abstract 3050
Background
Although surgical resection is the main treatment for rectal cancer, the optimal surgical protocol for elderly patients with rectal cancer remains controversial. Robot-assisted surgery has the following advantages: smaller wounds, less blood loss, quicker recovery, early recovery, and high rate of anal preservation. This study evaluated the feasibility of robot-assisted surgery in elderly patients with rectal cancer.
Methods
This retrospective study enrolled 125 patients aged 28–93 years diagnosed with stage I–III rectal cancer who underwent robot-assisted surgery between May 2013 and April 2018 in a single institution.
Results
In total, 125 patients with rectal cancer, including 100 nonelderly (aged <70 years) and 25 elderly (aged ≥70 years) patients, who underwent robot-assisted surgery were recruited. Between the patient groups, the incidence of overall postoperative complications and postoperative length of hospital stay did not differ significantly (p = 0.930 and 0.095, respectively). No surgical related deaths were noted. The disease-free and overall survival did not differ significantly between the 2 groups (p = 0.610 and 0.298, respectively).
Conclusions
Robot-assisted surgery for rectal cancer is an appropriate approach that is well tolerated in elderly patients, with similar results as for the non-elderly patients. Oncological outcomes, including postoperative complications and survival, did not depend on patient age. Thus, in elderly patients, robot-assisted surgery is a safe and feasible surgical modality for treating operable rectal cancer and leads to age-independent postoperative outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Wei-Chih Su.
Funding
Kaohsiung Medical University Hospital.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4732 - Progesterone Receptor Isoform Ratio Dictates Antiprogestins/Progestins Effects on Metastatic Breast Cancer Models
Presenter: Maria Abascal
Session: Poster Display session 2
Resources:
Abstract
5737 - PAM50 and CGH-array genomic characterization of HER2-Equivocal Breast Cancers defined by the 2018 ASCO/CAP recommendations.
Presenter: Carine Ngo
Session: Poster Display session 2
Resources:
Abstract
1096 - OncotypeDX® predictive nomogram for recurrence score output: a machine learning system based on quantitative immunochemistry analysis - ADAPTED01
Presenter: Fabio Marazzi
Session: Poster Display session 2
Resources:
Abstract
5426 - Geriatric parameters predict both disease-related and patient-reported outcomes in older patients with breast cancer
Presenter: Willeke van der Plas-Krijgsman
Session: Poster Display session 2
Resources:
Abstract
5865 - Patients with a 21-gene assay in South East London differ from the TAILORx trial population
Presenter: Charalampos Gousis
Session: Poster Display session 2
Resources:
Abstract
1312 - Predictive tools in adjuvant breast cancer – what is the standard of evidence supporting their utility? A literature review examining validation of Adjuvant!, Cancermath and NHS Predict
Presenter: Alice Loft
Session: Poster Display session 2
Resources:
Abstract
2445 - Oncologic outcome of invasive lobular carcinoma: Is it different from that of invasive ductal carcinoma?
Presenter: Hee Jun Choi
Session: Poster Display session 2
Resources:
Abstract
2476 - Pathologic response and survival efficacy in patients with initial nodal involvement after neoadjuvant chemotherapy in early breast cancer
Presenter: SERAFIN MORALES Murillo
Session: Poster Display session 2
Resources:
Abstract
3761 - Chemotherapy-induced amenorrhea: prognostic impact on premenopausal Egyptian patients with breast cancer
Presenter: Khaled Abdel Karim
Session: Poster Display session 2
Resources:
Abstract
4687 - Predicting the presence of breast cancer using circulating small RNA in the serum
Presenter: Yumiko Koi
Session: Poster Display session 2
Resources:
Abstract